Patents by Inventor James E. Juul

James E. Juul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11529346
    Abstract: A composition having gel-like consistency contains metronidazole, terconazole, a physiologically acceptable thickener and water. The composition is useful for treating bacterial vaginosis as well as vulvovaginal candidiasis.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: December 20, 2022
    Assignee: National Medical Supply, LLC
    Inventors: Robert J. Borgman, James E. Juul
  • Publication number: 20210393619
    Abstract: A composition having gel-like consistency contains metronidazole, terconazole, a physiologically acceptable thickener and water. The composition is useful for treating bacterial vaginosis as well as vulvovaginal candidiasis.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 23, 2021
    Applicant: National Medical Supply, LLC
    Inventors: Robert J. Borgman, James E. Juul
  • Patent number: 10398692
    Abstract: An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of citric acid. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: September 3, 2019
    Assignee: Curatek Pharmaceuticals Holding, Inc.
    Inventors: Robert J. Borgman, James E. Juul
  • Patent number: 9211286
    Abstract: An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of an organic acid. Preferably the organic acid is a water soluble alkyl carboxylic acid, a polybasic organic acid, or a combination thereof. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: December 15, 2015
    Assignee: Curatek Pharmaceuticals Holding, Inc.
    Inventors: Robert J. Borgman, James E. Juul
  • Publication number: 20150265609
    Abstract: An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of citric acid. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole.
    Type: Application
    Filed: June 2, 2015
    Publication date: September 24, 2015
    Inventors: Robert J. Borgman, James E. Juul
  • Patent number: 8258164
    Abstract: An aqueous nitroimidazole composition comprises metronidazole, tinidazole or a combination thereof at a concentration greater than the solubility of the free base form of the nitroimidazole in water at 20° C., and a nitroimidazole crystallization-inhibiting amount of at least one organic acid. The organic acid preferably is a lower alkyl carboxylic acid (e.g., acetic acid), a polybasic acid (e.g., citric acid, tartaric acid, malic acid, polyacrylic acid, and the like), or a combination thereof. The composition can further include a thickening agent, to form a gel. The composition is free from organic co-solvents, water-soluble vitamins, and cyclodextrins; and free from nitroimidazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: September 4, 2012
    Assignee: Curatek Pharmaceuticals Holding, Inc.
    Inventors: Robert J. Borgman, James E. Juul
  • Publication number: 20080063670
    Abstract: An aqueous nitroimidazole composition comprises metronidazole, tinidazole or a combination thereof at a concentration greater than the solubility of the free base form of the nitroimidazole in water at 20° C., and a nitroimidazole crystallization-inhibiting amount of at least one organic acid. The organic acid preferably is a lower alkyl carboxylic acid (e.g., acetic acid), a polybasic acid (e.g., citric acid, tartaric acid, malic acid, polyacrylic acid, and the like), or a combination thereof. The composition can further include a thickening agent, to form a gel. The composition is free from organic co-solvents, water-soluble vitamins, and cyclodextrins; and free from nitroimidazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described.
    Type: Application
    Filed: September 12, 2006
    Publication date: March 13, 2008
    Inventors: Robert J. Borgman, James E. Juul
  • Publication number: 20080063669
    Abstract: An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of an organic acid. Preferably the organic acid is a water soluble alkyl carboxylic acid, a polybasic organic acid, or a combination thereof. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole.
    Type: Application
    Filed: September 12, 2006
    Publication date: March 13, 2008
    Inventors: Robert J. Borgman, James E. Juul
  • Publication number: 20080063668
    Abstract: An aqueous tinidazole and terconazole composition comprises at least about 0.5 percent by weight of tinidazole and about 0.4 to about 3 percent by weight of terconazole dissolved in water, and a crystallization-inhibiting amount of an organic acid. Preferably the organic acid is citric acid. The composition is free from crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described.
    Type: Application
    Filed: September 12, 2006
    Publication date: March 13, 2008
    Inventors: Robert J. Borgman, James E. Juul
  • Patent number: 6913759
    Abstract: A pharmaceutical composition having a gel consistency at room temperature and suitable for the treatment of a vaginal infection comprises, on a total composition weight basis, about 0.1 to about 3 weight percent of benzydamine hydrochloride, about 16 to about 35 weight percent of a polyoxyalkylene block copolymer, and about 2 to about 30 weight percent of propylene glycol, in water having a pH value in the range of about 3.5 to about 7. The weight ratio of water to polyoxyalkylene block copolymer in the composition is less than about 4:1. Optionally, the gel compositions can also contain glycerin, physiologically tolerable preservatives and buffers, as well as other pharmaceutically acceptable excipients.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: July 5, 2005
    Assignee: Curatek Pharmaceuticals Holding, Inc.
    Inventors: Robert J. Borgman, James E. Juul
  • Publication number: 20040180965
    Abstract: A pharmaceutical composition having a gel consistency at room temperature and suitable for the treatment of a vaginal infection comprises, on a total composition weight basis, about 0.1 to about 3 weight percent of benzydamine hydrochloride, about 16 to about 35 weight percent of a polyoxyalkylene block copolymer, and about 2 to about 30 weight percent of propylene glycol, in water having a pH value in the range of about 3.5 to about 7. The weight ratio of water to polyoxyalkylene block copolymer in the composition is less than about 4:1. Optionally, the gel compositions can also contain glycerin, physiologically tolerable preservatives and buffers, as well as other pharmaceutically acceptable excipients.
    Type: Application
    Filed: March 11, 2003
    Publication date: September 16, 2004
    Inventors: Robert J. Borgman, James E. Juul
  • Publication number: 20040131686
    Abstract: A gelled pharmaceutical composition suitable for the treatment of a bacterial vaginal infection comprises, on a total composition weight basis, about 0.1 to about 2 weight percent of benzydamine hydrochloride, about 0.5 to about 4 weight percent of a carbomer polymer, and about 3 to about 50 weight percent of propylene glycol, in water having a pH in the range of about 3.5 to about 6. Optionally, the gelled compositions can also contain polyethylene glycols, physiologically tolerable preservatives and electrolytes, as well as other pharmaceutically acceptable excipients.
    Type: Application
    Filed: January 6, 2003
    Publication date: July 8, 2004
    Inventors: Robert J. Borgman, James E. Juul